Clinical trialNCT00271596CompletedPhase 2Interventional

Citalopram to Enhance Cognition in HD

SponsorUniversity of IowaEnrollment33ChoreaExecutive DysfunctionHuntington Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status, 2. To study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and 3. To examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jess G Fiedorowicz, M.D., Ph.D.
University of Iowa Psychiatry Department
Principal Investigator
clinicaltrials.gov ↗
John Caviness, M.D.
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗
Kevin Biglan, M.D., M.P.H.
University of Rochester
Principal Investigator
clinicaltrials.gov ↗
Leigh J Beglinger, Ph.D.
The University of Iowa Psychiatry Department
Principal Investigator
clinicaltrials.gov ↗
Ricardo Jorge, M.D.
University of Iowa Psychiatry Department
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Arizona
Scottsdale, Arizona, United States
the University of Iowa
Iowa City, Iowa, United States
University of Rochester
Rochester, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

20mg daily citalopramPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2005
Primary completion: 30 Apr 2011
Completion: 30 Nov 2011
Last update posted: 13 Mar 2013
Registered enrollment: 33
Registry id: NCT00271596

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.